EDITION:

Search
Search
Close this search box.

Cannabinoids for glioblastoma: MGC Pharma announces pre-clinical trial results

Home » Cannabinoids for glioblastoma: MGC Pharma announces pre-clinical trial results

MGC Pharmaceuticals has collaborated with the National Institute of Biology in Slovenia to carry out a three year pre-clinical in vitro research into the use of cannabinoids in the treatment of glioblastoma.

Glioblastoma is a fast-growing and aggressive form of brain tumour, with current treatments consisting of surgery, radiotherapy, chemotherapy and targeted drug therapy. Surviving a Glioblastoma is not common, with only a handful of patients living past two and half years after diagnosis, and less than 5 per cent living beyond five years after diagnosis.

MGC Pharma’s pre-clinical study, undertaken on 30 biopsy samples from 18 patients, sought to determine the optimal formulation for the treatment of the aggressive brain tumour, including the most efficacious ratio of CBD to CBG.

Read more: Phytocannabinoid company MGC Pharma initiates study for long-COVID

The company claims that its proprietary formulations were cytotoxic to glioblastoma tumours and stem cells, reducing the cells’ viability and inducing caspase-dependent cell apoptosis – “cell death”. Glioblastoma stem cells being the main cause of the disease’s progression, and are highly resistant to standard therapies.

It has also stated that tests conducted on the glioblastoma biopsy samples demonstrated that the CBD/CBG treatment’s efficacy was not enhanced by the addition of a widely used chemotherapy treatment, which has been linked to adverse events.

Co-founder and managing director of MGC Pharmaceuticals, Roby Zomer, commented: “The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumours. 

“MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumours without the use of toxic chemotherapy components. 

“We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials.”

MGC Pharma is also undertaking studies in collaboration with UK company, Graft Polymer UK PLC, on the use of a base formulation nano delivery system, based on Graft Polymer’s Graft-Bio IP, to improve the bioavailability of the active compounds using a non-invasive drug administration process, with the study examining the toxicity of the base emulation in order to confirm its safety profile for potential use in its future clinical research.

The company is now planning to undertake additional research to further demonstrate the formulation’s efficacy as a treatment for Glioblastoma.

[activecampaign form=31]

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?